The phase II FIGHT-202 trial evaluated the use of pemigatinib in the second line for patients with CC harboring FGFR2 fusions or rearrangements and demonstrated an ORR of 35.5% and an impressive mOS of 21.1 months, thus emerging as an option for patients with tumors that progressed to a platinum-based regimen [32]. Here, FGFR2 is linked to cholangiocarcinoma.